ClinicalTrials.gg
RecruitingNCT06136689COMP-ASUpdated Nov 18, 2023

Role of Aortic Valve Composition in Pathophysiology and Diagnosis of Aortic Stenosis

An observational study in Aortic Stenosis, Aortic Valve Disease and Aortic Valve Calcification, sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Medical University of Warsaw · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Aortic Valve Stenosis with a site in Poland — 10 open to participants now, 11 under way, 1 of them phase 3. Aortic Valve Stenosis · Poland.

Planned enrollment
13th of 14
55 · median 250
Started
2022
with 1 other
Observational
14 of 30
5 open now
Primary completion
2025-01
later than 4 of 10 live
Registered
25th of 30
by date
Lead sponsor
5 of 30
Medical University of Warsaw

Among the 30 studies in Aortic Valve Stenosis with a site in Poland, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2022, is one of 14 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 25th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 30 studies in Aortic Valve Stenosis with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Aortic Valve Stenosis with a site in Poland, or all of them as a file.
02

Study summary

The study aims to evaluate composition differences of aortic valves in different stages and phenotypes of aortic stenosis using non-invasive imaging and histology.

03

Conditions studied

  • Aortic Stenosis
  • Aortic Valve Disease
  • Aortic Valve Calcification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will involve patients undergoing surgical aortic valve replacement (SAVR) for different phenotypes of severe AS (high-flow high-gradient, classical low-flow low-gradient, and paradoxical low-flow low-gradient) or moderate AS with coexisting aortic aneurysm as part of Bentall procedure. Patients undergoing heart transplant will be considered control group without aortic valve stenosis.

Eligibility criteria

Inclusion Criteria:

  • aortic valve replacement or heart transplant as part of standard care decided by the local Heart Team
  • pre-surgical computed tomography angiography
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Severe Aortic Stenosis - High Flow, High Gradient

    patients undergoing surgical aortic valve replacement for severe AS

  • Severe Aortic Stenosis - classical Low Flow, Low Gradient

    patients undergoing surgical aortic valve replacement for severe AS

  • Severe Aortic Stenosis - paradoxical Low Flow, Low Gradient

    patients undergoing surgical aortic valve replacement for severe AS

  • Moderate Aortic Stenosis

    patients undergoing aortic root replacement (Bentall procedure)

  • Heart Transplant

    patients undergoing orthotopic heart transplant for any reason

06

What researchers measure

Primary outcomes

  1. Aortic valve tissue composition measured from pre-procedural computed tomography angiography

    Quantitative analysis of aortic valve composition will be based on pre-surgical planning CTA images using semi-automated software (Autoplaque version 2.5, Cedars-Sinai Medical Center, Los Angeles, CA, USA) for calcified, non-calcified and total tissue volumes.

    Time frame: up to 30-days before surgery

  2. Aortic valve tissue composition measured from quantitative histology

    Different stains will be used to characterize composition of excised aortic valves (hematoxylin and eosin, Movat Pentachrome, Van Gieson's trichrome, Congo Red, anti-CD68 antibody

    Time frame: immediately post-surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Grodecki K, Tamarappoo BK, Huczek Z, Jedrzejczyk S, Cadet S, Kwiecinski J, Rymuza B, Parma R, Olasinska-Wisniewska A, Fijalkowska J, Protasiewicz M, Walczak A, Nowak A, Gocol R, Slomka PJ, Reczuch K, Jagielak D, Grygier M, Wojakowski W, Filipiak KJ, Dey D. Non-calcific aortic tissue quantified from computed tomography angiography improves diagnosis and prognostication of patients referred for transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2021 May 10;22(6):626-635. doi: 10.1093/ehjci/jeaa304. PubMed 33247903 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2025, 36 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 36 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 18, 2023
StartActual
Jan 1, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
May 1, 2025
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06136689
Collaborators
Polish Cardiac Society
Responsible party
Kajetan Grodecki (Principal Investigator, Medical University of Warsaw) — Principal investigator
First posted
Nov 18, 2023
Start date
Jan 1, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Nov 18, 2023

Study contacts

Kajetan Grodecki, MD, PhD
Contact
kajetan.grodecki@gmail.com
0048 660675782
Zenon Huczek, MD,PhD
study director · Medical University of Warsaw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion